Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Blueprint Medicines Corp (NASDAQ: BPMC) was $98.76 for the day, down -1.04% from the previous closing price of $99.80. In other words, the price has decreased by -$1.04 from its previous closing price. On the day, 0.8 million shares were traded.
Ratios:
Our analysis of BPMC’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 2.08 whereas as Long-Term Debt/Eq ratio is at 1.72.
On March 17, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $135.Jefferies initiated its Buy rating on March 17, 2025, with a $135 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 05 ’25 when Rossi Christina sold 2,274 shares for $101.75 per share. The transaction valued at 231,386 led to the insider holds 66,992 shares of the business.
Hurley Ariel sold 2,752 shares of BPMC for $283,819 on May 05 ’25. The PRINCIPAL ACCOUNTING OFFICER now owns 16,944 shares after completing the transaction at $103.13 per share. On May 05 ’25, another insider, ARIEL HURLEY, who serves as the Officer of the company, bought 2,942 shares for $104.64 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 11.35 while its Price-to-Book (P/B) ratio in mrq is 18.64.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $121.90, while it has fallen to a 52-week low of $73.04. The 50-Day Moving Average of the stock is 11.05%, while the 200-Day Moving Average is calculated to be 5.49%.
Shares Statistics:
A total of 64.56M shares are outstanding, with a floating share count of 63.31M. Insiders hold about 1.97% of the company’s shares, while institutions hold 104.41% stake in the company.
